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Aims Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused
by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either
ischaemic or non-ischaemic HF, it is important to better understand differences in underlying molecular mechanisms.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We performed a biological physical protein–protein interaction network analysis to identify pathophysiological
pathways distinguishing ischaemic from non-ischaemic HF. First, differentially expressed plasma protein biomarkers
were identified in 1160 patients enrolled in the BIOSTAT-CHF study, 715 of whom had ischaemic HF and 445
had non-ischaemic HF. Second, we constructed an enriched physical protein–protein interaction network, followed
by a pathway over-representation analysis. Finally, we identified key network proteins. Data were validated in an
independent HF cohort comprised of 765 ischaemic and 100 non-ischaemic HF patients. We found 21/92 proteins
to be up-regulated and 2/92 down-regulated in ischaemic relative to non-ischaemic HF patients. An enriched
network of 18 proteins that were specific for ischaemic heart disease yielded six pathways, which are related to
inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. We identified five key
network proteins: acid phosphatase 5, epidermal growth factor receptor, insulin-like growth factor binding protein-1,
plasminogen activator urokinase receptor, and secreted phosphoprotein 1. Similar results were observed in the
independent validation cohort.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions Pathophysiological pathways distinguishing patients with ischaemic HF from those with non-ischaemic HF were
related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. The five
key pathway proteins identified are potential treatment targets specifically for patients with ischaemic HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Ischaemic heart failure • Heart disease • Physical protein–protein interaction • Pathway •
Cardiomyopathy
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Introduction
Heart failure (HF) is a clinical syndrome with multiple underlying
causes, which are broadly classified as ischaemic vs. non-ischaemic.
Myocardial dysfunction subsequent to ischaemic heart disease and
impaired blood supply due to atherosclerosis and the presence of
scar formation and remodelling are considered to be main drivers
of ischaemic HF. Non-ischaemic HF is considered as a primary
disease of the myocardial cell and interstitium. Guideline-directed
therapies targeting HF are the same regardless of aetiology.1
In contrast to morphological studies, clinical data on differences
in molecular mechanisms between ischaemic and non-ischaemic HF
are scarce. Pathway analysis using multiple circulating biomarkers is
a well-validated method to elucidate pathophysiological pathways
that are typically related to a specific phenotype. We recently
performed such a network analysis to distinguish HF patients
with a preserved vs. reduced left ventricular ejection fraction
(LVEF).2
Incremental and distinct from our previous work, in the present
study, we performed network analyses based on differential protein
expression coupled with biological physical protein–protein inter-
action, and clinical outcome, to identify pathophysiological path-
ways distinguishing ischaemic from non-ischaemic HF.
Methods
Patient population and study design
We performed our analyses on the BIOlogy Study to TAilored
Treatment in Chronic Heart Failure (BIOSTAT-CHF).3 Briefly,
BIOSTAT-CHF consists of two independent cohorts. The index
cohort included 2516 patients with worsening signs and/or symptoms
of HF from 11 European countries. The validation cohort is an inde-
pendent cohort of 1738 HF patients from Scotland. The design and
baseline characteristics of both cohorts of BIOSTAT-CHF have been
published elsewhere.3 Inclusion criteria were the same in the index
and validation cohorts, except that in case LVEF was more than 40%,
there was a B-type natriuretic peptide (BNP)/N-terminal pro BNP
(NT-proBNP) threshold of respectively >400 pg/mL or> 2000 pg/mL
in the index cohort, but not in the validation cohort. The study
complied with the Declaration of Helsinki and was approved by
the medical ethics committees of participating centres. Herein, we
classified patients into two groups; ischaemic HF or non-ischaemic HF
based on their medical and clinical histories and availability of study
biomarker data (Figure 1).
Study group definition
From both BIOSTAT index and validation cohorts, we classified
ischaemic HF patients as (i) those who were considered by the recruit-
ing investigators to have an ischaemic aetiology (BIOSTAT-CHF case
report form required investigators to fill in the primary aetiology of
HF), and (ii) those who had a history of documented myocardial infarc-
tion. The non-ischaemic group of HF patients are (i) those who were
considered by the recruiting investigator to have a cardiomyopathy; and
(ii) those who had no evidence for any form of ischaemic heart disease
(i.e. did not have a previous myocardial infarction, percutaneous coro-
nary intervention and/or coronary artery bypass surgery). All patients,
irrespective of LVEF, that met the study group definitions were eligible. ..
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The protein biomarker data used for this study have been described
in recent papers.4,5 In brief, we used the Cardiovascular III (CVDIII)
panel of 92 cardiovascular disease-related proteins provided by Olink
Bioscience analysis service (Uppsala, Sweden). The proteins were
profiled using the Olink Proseek® Multiplex Inflammatory96*96 plat-
form (details in online supplementary material and supplementary
Table S1).
Differential protein expression analyses
Differential protein expression analysis was done by simply tether-
ing the fold change of the 92 protein biomarkers in ischaemic vs.
non-ischaemic patients for the index and validation cohorts. A min-
imal fold change of 1.15 yielded consistent results between patients
in the index and validation cohort (online supplementary Figure S1).
This threshold was subsequently applied to a more complicated dif-
ferential expression analysis using the Linear Models for Microar-
ray data analysis (Limma)6 software (version 3.34.9). Analyses were
done at a fold change threshold of 1.15, P-value and false discov-
ery rate (FDR) <0.05. Proteins that met these cutoffs were consid-
ered differentially expressed in ischaemic relative to non-ischaemic
HF patients. In practice, the P-value is lower than the FDR, so effec-
tive differential expression hits are determined by the fold change
and FDR.
Construction of enriched physical
protein–protein interaction networks
We constructed a comprehensive biological network of human physical
protein–protein interactions (NR_HsapiensPPI; details in online sup-
plementary material), consisting of 17 625 unique nodes with 330 157
interactions. These protein–protein interactions are not based on
in-silico predictions, but are rather biologically determined and manu-
ally curated and stored in secondary databases used in this manuscript.
We have rendered these into current terms to enable integration
with contemporary data analyses to ensure minimal information loss.
The biological methods used to detect physical interactions are pre-
sented in online supplementary Figure S6, and are mainly based on
two-hybrid, and/or affinity purification followed by mass spectrometry
methodologies.7–12
From the general ‘NR_HsapiensPPI’ network, we harvested an
‘Olink PPI network’ as the subnetwork that contains nodes (and
associated interactions) belonging to any of the 92 Olink protein
biomarkers. We checked the cohesiveness of the ‘Olink PPI network’
using the physical interaction enrichment (PIE) algorithm,13 which
corrects for inquisitional bias in biological networks for proteins
that are often studied. The ‘Olink PPI network’ was found to be a
significant physically cohesive network (PIE score = 1.24, P = 0.004)
(online supplementary Figure S2). This ‘Olink PPI network’ was used
for subsequent network enrichment analyses.
Pathway over-representation analyses
We assessed over-representation with ClueGO14 (in Gene Ontology
biological processes, KEGG and Reactome pathways) using the hyper-
geometric test and the default Bonferroni step down method for mul-
tiple testing corrections (family-wise error rate). We used the whole
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Consort diagram. Selection of ischaemic and non-ischaemic heart failure patients from both BIOSTAT-CHF cohorts. CABG,
coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention.
annotation option as reference set and reported only biological pro-
cesses with a corrected P-value ≤0.05 to be significant.
Identification of key network proteins
Using the physically cohesive ‘Olink PPI network’ as template, we
constructed a subnetwork by propagating [up to one neighbourhood
away (N1-propagation)] interactions between proteins up-regulated
in ischaemic relative to non-ischaemic patients to yield an enriched
network. An N1-propagation minimizes loss of context (concept in
online supplementary Figure S1) and would capture any of the 92 pro-
teins having a previously established biological physical protein–protein
interactions in the network knowledgebase. To enhance our under-
standing of the identified pathophysiological pathways, we identified
the network proteins therein that were associated with mortality.
Statistical analysis
Statistical analyses were done in R.15 In group comparisons, categor-
ical variables were depicted as numbers with percentages. Normally
distributed variables were depicted as means± standard deviation,
non-normally distributed variables as median with the first and third
quartile (Q1–Q3). The means for continuous variables were com-
pared by one-way analysis of variance (ANOVA) or the Kruskal–Wallis
test, while categorical variables were compared by the Chi-squared
test. Kaplan–Meier survival curves were compared using the log-rank
statistic. Cox regression models were used to adjust for the effect
of covariates and to calculate hazard ratios (HR). Cox proportional
hazards assumptions were assessed (using the R-based Survival and
Survminer packages) by visual inspection of Schoenfeld residuals against
time plots. For additional pathway-level analyses, time-dependent area ..
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.. under receiver operating curve (AUCt) were obtained in a univari-
ate fashion (per biomarker) and in aggregates (pathway biomarkers).
AUCt is a measure of the discriminative ability of a marker at each
time point under consideration. An AUCt <0.5 indicates decreasing
while AUCt >0.5 indicates increasing mortality rate (in this study).
The R-package, survivalROC was used for AUCt calculations. Baseline
tables and univariate analyses were done using the R-based Compare-
Groups package. In general, a two-tailed P-value of <0.05 was consid-
ered statistically significant.
Results
Baseline characteristics
From the 2516 HF patients of the BIOSTAT-CHF index cohort we
identified 715 patients with Olink-CVDIII data who met the strin-
gent criteria for ischaemic HF and 445 patients with Olink-CVDIII
data who met the stringent criteria for non-ischaemic HF. Patients
in both groups were mainly men (82% in the ischaemic group and
73% in the non-ischaemic group; P< 0.001). Baseline characteris-
tics of ischaemic vs. non-ischaemic HF patients are shown in Table 1.
Ischaemic patients were older, had significantly lower heart rates
and a more frequent history of HF hospitalization and smoking.
In both study groups, most patients had either HF with reduced
or mid-range LVEF and there was no significant difference in the
prevalence of HF with preserved LVEF between the groups with
ischaemic and non-ischaemic HF. Baseline characteristics of the
patients in the validation cohort showed similar trends (online sup-
plementary Table S2).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of the index cohort stratified by ischaemic and non-ischaemic heart failure
Demographics and medical history Ischaemic
(n = 715)
Non-ischaemic
(n = 445)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male sex 585 (81.8) 324 (72.8) <0.001
Age (years) 71.0 [63.0–78.0] 64.0 [54.0–73.0] <0.001
Ischaemic heart disease <0.001
Primary 715 (100) 0 (0.00)
Not present 0 (0.00) 382 (85.8)
Unknown 0 (0.00) 63 (14.2)
Hypertension <0.001
Primary 16 (2.24) 0 (0.00)
Contributory 401 (56.1) 153 (34.4)
Not present 284 (39.7) 277 (62.2)
Unknown 14 (1.96) 15 (3.37)
Cardiomyopathy <0.001
Primary 5 (0.70) 445 (100)
Contributory 135 (18.9) 0 (0.00)
Not present 543 (75.9) 0 (0.00)
Unknown 32 (4.48) 0 (0.00)
Valvular disease 0.150
Primary 5 (0.70) 0 (0.00)
Contributory 220 (30.8) 155 (34.8)
Not present 471 (65.9) 276 (62.0)
Unknown 19 (2.66) 14 (3.15)
Previous HF hospitalization(s) in last year 272 (38.0) 136 (30.6) 0.011
Myocardial infarction 715 (100) 0 (0.00) <0.001
CABG 263 (36.8) 0 (0.00) <0.001
Valvular surgery 44 (6.15) 15 (3.37) 0.050
PCI 339 (47.4) 0 (0.00) <0.001
Atrial fibrillation 276 (38.6) 189 (42.5) 0.213
Stroke 92 (12.9) 24 (5.39) <0.001
Peripheral arterial disease 116 (16.2) 20 (4.49) <0.001
Hypertension 495 (69.2) 188 (42.2) <0.001
Smoking <0.001
None 180 (25.2) 196 (44.0)
Past 437 (61.2) 183 (41.1)
Current 97 (13.6) 66 (14.8)
Current alcohol use 188 (26.3) 139 (31.2) 0.082
Diabetes 290 (40.6) 99 (22.2) <0.001
Diet 192 (66.2) 68 (68.7) 0.742
Insulin 130 (44.8) 37 (37.4) 0.240
Oral anti-diabetic drugs 169 (58.3) 61 (61.6) 0.642
COPD 137 (19.2) 61 (13.7) 0.020
Renal disease 258 (36.1) 84 (18.9) <0.001
Current malignancy 23 (3.22) 13 (2.92) 0.914
Physical examinations
Height (cm) 172 [165–177] 172 [167–179] 0.026
Weight (kg) 80.0 [70.0–90.0] 81.0 [70.0–93.0] 0.194
Heart rate (bpm) 72.0 [64.0–81.0] 76.0 [68.0–88.5] <0.001
Systolic blood pressure (mmHg) 120 [110–135] 120 [109–130] 0.375
Diastolic blood pressure (mmHg) 70.0 [65.0–80.0] 73.0 [68.0–80.0] 0.014
Pulmonary congestion/oedema with rales/crackles <0.001
No 307 (44.6) 247 (57.0)
Single base 84 (12.2) 54 (12.5)
Bi-basilar 297 (43.2) 132 (30.5)
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 (Continued)
Demographics and medical history Ischaemic
(n = 715)
Non-ischaemic
(n = 445)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Elevated JVP 0.342
No 329 (63.8) 216 (67.1)
Yes 167 (32.4) 90 (28.0)
Uncertain 20 (3.88) 16 (4.97)
Signs and symptoms of HF
NYHA class 0.086
I 11 (1.58) 11 (2.52)
II 248 (35.6) 181 (41.5)
III 339 (48.6) 196 (45.0)
IV 99 (14.2) 48 (11.0)
Dyspnoea VAS score 50.0 [30.0–65.0] 60.0 [40.0–70.0] 0.031
LVEF (%) 30.0 [25.0–35.0] 26.5 [21.2–31.8] <0.001
HFrEF (LVEF <40%) 545 (86.1) 387 (93.5) <0.001
HFmrEF (LVEF 40–<50%) 75 (11.8) 21 (5.07) <0.001
HFpEF (LVEF ≥ 50%) 13 (2.05) 6 (1.45) 0.631
Orthopnoea present 245 (34.4) 141 (31.8) 0.395
Medications
ACEi/ARB 497 (69.5) 354 (79.6) <0.001
Beta-blocker 634 (88.7) 380 (85.4) 0.122
Aldosterone antagonist 396 (55.4) 266 (59.8) 0.159
Diuretics 715 (100) 444 (99.8) 0.384
Statin 545 (76.2) 159 (35.7) <0.001
Laboratory data
Serum creatinine (μmol/L) 110 [89.2–142] 95.5 [79.6–119] <0.001
LDL (mmol/L) 2.30 [1.64–2.96] 2.90 [2.16–3.48] <0.001
NT-proBNP (pg/mL) 2831 [1246–5868] 2130 [906–4734] 0.002
Mortality
All-cause death 201 (28.1) 76 (17.1) <0.001
Cardiovascular death 142 (19.9) 47 (10.6) <0.001
Values are given as n (%), or median [interquartile range].
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; HF,
heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;
JVP, jugular venous pressure; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York
Heart Association; PCI, percutaneous coronary intervention; VAS, visual analogue scale.
Results of differential protein expression
analyses
Differential protein expression in ischaemic vs. non-ischaemic HF
patients yielded 23/92 differentially expressed proteins amongst
which 21 were up-regulated and 2 down-regulated (Figure 2).
The two most prominently up-regulated proteins in patients with
ischaemic HF were galectin 4 (LGALS4) and growth differentiation
factor 15 (GDF15), while paraoxonase 3 (PON3) was the most
prominently down-regulated protein in patients with ischaemic
HF. These differences remained statistically significant after cor-
rection for age, sex and the use of statins at baseline (online
supplementary Figure S3). The differentially expressed proteins in
the validation cohort largely overlapped with those in the index
cohort (Figure 2B).
In addition, the differential expression results were consistent
between both cohorts as no protein was found to be up-regulated
in one cohort but down-regulated in the other, or vice versa. For ..
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. brevity, detail results for the index cohort are presented in online
supplementary Table S3.
Results of enriched physical
protein–protein interaction network
The 21/92 up-regulated proteins in ischaemic vs. non-ischaemic
HF patients yielded an enriched network consisting of 18 proteins
(online supplementary Figure S4). In non-ischaemic HF patients,
only two proteins were up-regulated, which was insufficient to
build a network. Therefore, we focused on networks specific for
ischaemic HF.
Results of pathway over-representation
analyses
Pathway over-representation analyses of the 21 up-regulated pro-
teins in ischaemic HF patients led to the identification of only two
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A
B
Figure 2 Differential protein expression in ischaemic relative to non-ischaemic heart failure (HF) patients. (A) Volcano plot of differential
protein expression (y-axis significance, x-axis effect size (positive = up-regulated, negative = down-regulated; labelled = significant differentially
expressed proteins). (B) Venn diagram of number of significantly differentially expressed proteins index cohort (main) and validation cohort.
Consistently, no proteins were up-regulated in one cohort but down-regulated in the other, nor vice versa. FC, fold change; FDR, false discovery
rate; TNF, tumour necrosis factor.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Pathophysiological pathways related to ischaemic heart failure. Proteins (small nodes) linking the pathways (large nodes) are depicted.
The six-pathway modules are labelled by the most significant group term. The five-protein nodes highlighted were significantly associated with
mortality. ACP5, acid phosphatase 5; CHI3L1, chitinase-3-like protein 1; DLK1, delta like non-canonical notch ligand 1; EGFR, epidermal
growth factor; GRN, progranulin; IGFBP1, insulin-like growth factor binding protein 1; IGFBP2, insulin-like growth factor binding protein
2; ITGB2, integrin subunit beta 2; LGALS3, galectin 3; MMP3, matrix metalloproteinase 3; PLAT, plasminogen activator, tissue type; PLAU,
plasminogen activator, urokinase; PLAUR, plasminogen activator, urokinase receptor; SPP1, secreted phosphoprotein 1; TNFRSF1A, tumour
necrosis factor receptor superfamily member 1A; TNFRSF1B, tumour necrosis factor receptor superfamily member 1B; TRFC, transferrin
receptor.
pathways (regulation of cardiac muscle hypertrophy, and tumour
necrosis factors (TNFs) bind their physiological receptors), with
the majority of the proteins not successfully captured in the anal-
ysis (online supplementary Figure S5). We therefore proceeded to
perform pathway over-representation analysis of the enriched net-
work.
Using the 18 proteins of the enriched network (online sup-
plementary Figure S4) yielded six significant pathways (P< 0.001,
details in online supplementary Table S4) interconnected with each
other. This pathway network nexus is the main result of this study
and is presented in Figure 3. The six identified pathways/biological
processes are officially named ‘dissolution of fibrin clot’; ‘bone
resorption’; ‘regulation of superoxide anion generation’; ‘prostate
cancer’; ‘neuroinflammatory response’ and ‘regulation of cardiac
muscle hypertrophy’. ..
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.. Results of identification of key network
proteins associated with mortality
Out of the 18 proteins in the enriched network, five showed
significant associations with mortality, correcting for case study
group (i.e. ischaemic vs. non-ischaemic) and the other network
proteins. The Cox proportional hazard assumption was supported
by a non-significant relationship between residuals and time (global
P = 0.15). In addition, the independent variables did not indicate
multicollinearity (variance inflation factor<10). Amongst these
five key network proteins, increased levels of acid phosphatase 5
(ACP5) (HR 0.76, P = 0.045) and epidermal growth factor recep-
tor (EGFR) (HR 0.46, p = 0.005) were associated with significantly
lower risks of death, while increased levels of insulin-like growth
factor binding protein 1 (IGFBP1) (HR 1.19, P = 0.005), plasmino-
gen activator urokinase receptor (PLAUR) (HR 1.95, P = 0.009),
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Excerpts of biomarker association with all-cause mortality from multivariate Cox proportional hazards
regression analyses of enriched-network models
Protein biomarker HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Model 1 Model 2 Model 3
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Index cohort
ACP5 0.76 (0.58–0.99) 0.045 0.76 (0.58–1) 0.048 0.77 (0.59–1.01) 0.057
EGFR 0.46 (0.27–0.8) 0.005 0.48 (0.28–0.84) 0.010 0.47 (0.27–0.82) 0.008
IGFBP1 1.19 (1.06–1.35) 0.005 1.2 (1.06–1.35) 0.004 1.2 (1.07–1.36) 0.003
PLAUR 1.95 (1.18–3.21) 0.009 2.01 (1.22–3.32) 0.006 1.98 (1.2–3.27) 0.007
SPP1 1.47 (1.2–1.8) <0.001 1.47 (1.2–1.8) <0.001 1.46 (1.19–1.78) <0.001
Validation cohort
ACP5 0.7 (0.53–0.94) 0.016 0.72 (0.54–0.95) 0.022 0.7 (0.52–0.94) 0.016
EGFR 0.44 (0.23–0.83) 0.011 0.5 (0.26–1) 0.048 0.53 (0.27–1.06) 0.073
IGFBP1 1.23 (1.07–1.4) 0.003 1.22 (1.07–1.4) 0.004 1.23 (1.07–1.41) 0.003
PLAUR 2.3 (1.38–3.81) 0.001 2.47 (1.47–4.15) <0.001 2.44 (1.45–4.12) <0.001
SPP1 1.57 (1.2–2.07) 0.001 1.56 (1.18–2.05) 0.002 1.55 (1.18–2.05) 0.002
N/B: only significant results are shown.
ACP5, acid phosphatase 5, tartrate resistant; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; IGFBP1, insulin-like growth factor binding
protein 1; PLAUR, plasminogen activator, urokinase receptor; SPP1, secreted phosphoprotein 1.
Model 1: adjusted for enriched network nodes and study group.
Model 2: adjusted for Model 1 covariates, plus age and sex.
Model 3: adjusted for Model 2 covariates, plus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and beta-blocker use at baseline.
and secreted phosphoprotein 1 (SPP1) (HR 1.47, P< 0.001) were
associated with significantly higher risks of death (Table 2 and online
supplementary Figure S7). Therefore, these five proteins were iden-
tified as the five key pathway proteins.
Results of time-dependent area under
the curve analysis per pathway
To provide an overall prognostic impression of the protein
biomarkers together as a group per identified pathway, we per-
formed AUC(t) analyses. We observed an overall mortality drop
over time from baseline to about 15months. This was mainly
driven by four/six pathways (bone resorption, dissolution of fib-
rin clots, neuroinflammatory response and regulation of cardiac
muscle hypertrophy). For two/six pathways (i.e. prostate cancer
and regulation of superoxide anion generation) prognosis was bet-
ter and earlier. For these two pathways, although generally low in
both cohorts, mortality dropped from the first trimester in the
index cohort, but worsened (albeit at medium levels) over time in
the validation cohort (Figure 4).
Discussion
Using a physical protein–protein interaction network analysis to
identify pathophysiological pathways distinguishing ischaemic from
non-ischaemic HF, we showed that ischaemic HF pathways were
related to inflammation, endothelial dysfunction, superoxide pro-
duction, coagulation, and atherosclerosis. The network was con-
nected by 18 circulating proteins, of which five had a statistically
significant association with all-cause death. These five identified .
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.. proteins represent potential novel treatment targets specifically for
patients with ischaemic HF.
Differentially expressed proteins
Most of the proteins (75%) showed similar expression levels in
both disease populations, which suggests that there is a substantial
pathophysiological overlap between ischaemic and non-ischaemic
HF (at least as informed by the set of 92 proteins). The major-
ity of the differentially expressed proteins [21/23 (91%)] were
up-regulated in ischaemic vs. non-ischaemic HF patients, prompting
us to focus on the ischaemic phenotype in this manuscript.
Amongst the most prominent differentially expressed pro-
teins, LGALS4 and GDF15 were up-regulated while PON3 was
down-regulated in ischaemic vs. non-ischaemic HF patients. These
proteins remained significantly different even after correction for
age, sex and statin use. LGALS4 is involved in the regulation of
inflammation and promotion of angiogenesis.16 In animal studies,
GDF15 protected the heart through inhibition of hypertrophic,
inflammatory and apoptotic processes.17 PON3 is an inhibitor of
both oxidative modification of low-density lipoproteins and mono-
cyte activation, both of which are important stages in atheroscle-
rotic plaque formation.18 Lower levels of PON3 in the ischaemic
group might be associated with increased oxidation of low-density
lipoproteins leading to atherosclerosis.
The six interconnecting pathways related
to ischaemic heart failure
We identified the following six pathways in relation to ischaemic HF.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Temporal mortality prognostic trend of ischaemic nexus pathways. The time-dependent area under receiver operating curve
[AUC(t)] bins per 3 months (i.e. trimesters) for all six pathways are shown, in addition to those per pathway (left, index cohort; right, validation
cohort). Overall AUC(t) dropped over time. Although generally low in both cohorts, mortality prognostics based on two pathways (‘prostate
cancer’ and ‘regulation of superoxide anion generation’) dropped from the first trimester in the index cohort, but worsened (albeit at medium
levels) over time in the validation cohort.
Dissolution of fibrin clots
‘Dissolution of fibrin clots’ was the largest pathway identified and
involves the proteins plasminogen activator urokinase tissue type
(PLAT), plasminogen activator urokinase (PLAU), PLAUR and inte-
grin subunit beta 2 (ITGB2). ITGB2 is involved in the activation
of plasminogen on the surface of neutrophils.19 In addition, con-
version of plasminogen to plasmin, and subsequent promotion of
fibrinolysis is mediated by both PLAT and receptor bound PLAU.20
A study by Minami et al.21 reported that while acute up-regulation
of PLAU prevented rupture of the infarcted zone, chronic and per-
sistent activation of plasminogen through PLAUR–PLAU binding
may lead to fibrotic changes in uninjured myocardium. In addition,
several studies have reported macrophage-associated overexpres-
sion of PLAUR and PLAU in atherosclerotic lesions, leading to the
conclusion by Svensson et al.22 that the PLAU–PLAUR system may
play a vital role in plaque instability. In our study, higher levels of
PLAUR were also associated with increased risk of death.
Prostate cancer
The second pathway is officially labelled as ‘prostate cancer’, involv-
ing PLAU, PLAT, EGFR and matrix metalloproteinase 3 (MMP3).
Although we do not see a direct connection with prostate can-
cer, these proteins have potential associations with ischaemia,
atherosclerosis and neovascularization. The role of PLAT and PLAU
has been described under ‘dissolution of fibrin clots’. EGFR is not
only implicated in the promotion of tumour growth by promoting .
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. angiogenesis and revascularization,23 but EGFR signalling pathways
are also related to up-regulation of PLAU and PLAUR.24 Plasmin
is also capable of activating several MMPs, including MMP3, which
may lead to extracellular matrix degradation.23 Our network out-
come model indicated that EGFR was significantly associated with
lower mortality rates. This pathway is in close crosstalk with that
of the ‘dissolution of fibrin clots’ and warrants further investigation
in future studies.
Neuroinflammatory response
A third pathway is officially labelled as ‘neuroinflammatory
response’, and involves the proteins MMP3, EGFR, ITGB2 and
TNF receptor superfamily member 1B (TNFRSF1B). All of these
proteins are involved in the regulation of inflammatory pathways.
TNFRSF1B is implicated in T-cell-mediated immune responses.25
MMP3 is an important downstream activator of MMPs, including
MMP9 which is implicated in the cleavage of ITGB2 leading to
exodus of macrophages from the area of inflammation, which is
vital in limiting the local innate immune response.26 Collectively,
this implies a role for inflammatory pathways and their regulators
specifically in the pathophysiology of ischaemic HF.
Regulation of cardiac muscle hypertrophy
IGFBP1, TNFRSF1A and TNFRSF1B are implicated in the pathway
officially labelled as ‘regulation of cardiac muscle hypertrophy’
and are in crosstalk with the ‘neuroinflammation’ pathway. TNF
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receptors (TNFRSF1A1 and TNFRSF1B) mediate the downstream
cellular effects of TNF-𝛼, a pro-inflammatory cytokine important
for repair following tissue injury. However, persistent up-regulation
of TNF-𝛼 leads to chronic inflammation and is implicated in cardiac
dysfunction and HF.27
IGFBP1 is part of a protein family implicated in the regulation of
insulin-like growth factor I (IGF-I) bioavailability, transportation and
localization. The role of IGF-1 in HF is not completely understood.
However, there is growing evidence to suggest a pro-hypertrophic
effect of IGF-1 since IGFBP1 attenuated pro-hypertrophic effects
of IGF-1.28 We found that higher levels of IGFBP1were significantly
associated with increased mortality.
Regulation of superoxide anion generation
The fifth pathway identified is officially labelled as ‘regulation
of superoxide anion generation’, and involves ACP5, EGFR and
ITGB2. These proteins are in crosstalk with other pathways. Previ-
ous research has indicated that endothelial dysfunction present in
HF is due to superoxide-mediated inactivation of nitric oxide.29
ACP5-deficient mice reportedly exhibited increased superoxide
production, indicating its potential protective role in HF.30 On the
other hand, ITGB2 and EGFR mediate generation of superoxide
anions through downstream signalling. Higher levels of ACP5 and
EGFR were associated with lower risk of death.
Bone resorption
The final pathway identified is officially labelled as ‘bone resorp-
tion’, involving ACP5, EGFR, SPP1 and transferrin receptor. All four
proteins in this pathway have been identified to be up-regulated
in atherosclerosis.31–34 SPP1, involved in the attachment of osteo-
clasts to the mineralized bone matrix, is implicated in a variety
of cardiovascular diseases. Expression of SPP1 in the heart under
physiological conditions is low. However, its expression increases
dramatically after an acute myocardial infarction.31 Research in
both mice and humans has reported that increased SPP1 levels
are associated with fibrosis and systolic dysfunction.31,35 In our
study, increased levels of SPP1 were significantly associated with
increased mortality.
Therapies targeting the five key proteins
Amongst the five key proteins found, increased levels of ACP5
and EGFR were associated with improved clinical outcome while
IGFBP1, PLAUR and SPP1 were associated with worse clini-
cal outcome. In the Therapeutic Target Database36 (available at:
db.idrblab.net/ttd/), EGFR has been targeted (by e.g. cetuximab,
an antibody agent) for the treatment of inflammatory breast can-
cer and colorectal cancer. The other four remain to be tested.
Knock-out models or other perturbation of levels for these five tar-
gets would potentially enhance our understanding of their involve-
ment in ischaemic heart disease.
ACP5 [also known as tartrate-resistant acid phosphatase
(TRAP)] is involved in bone remodelling, a process that is gain-
ing increasing interest in arterial calcification. Arterial plaque ..
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.. calcification is highly prevalent, closely parallels atherosclerotic
burden and is related to risk of myocardial infarction and sud-
den cardiac death.37 Using immunohistochemical analysis (TRAP
enzyme staining), ACP5-positive multinucleated giant cells have
been observed in suture granulomas, necrotic plaque cores,
fibrotic/calcified plaque, and surrounded by foamy macrophages.38
The suggestion that these ACP5-positive cells might degrade
mineral deposits, prevent formation of calcification or both and
therefore counterbalance the activity of the osteoblast-like cells in
atherosclerosis38 corroborate our pro-life findings for ACP5 as an
interesting therapeutic target in ischaemic heart disease patients.
SPP1 also mediates cardiac fibrosis through the modulation
of cellular adhesion and proliferation and is increased in cardiac
hypertrophy. Studies on Spp1-knockout mice indicate that the lack
of SPP1 attenuates fibrosis.39
Regarding circulating PLAUR (which is also associated with
fibrosis and atherosclerosis), studies in humans indicate that higher
protein levels correlate with poorer cardiovascular outcomes and
are predictive of the presence of peripheral arterial disease.40
Likewise, higher levels of IGFBP1 were associated with higher risks
of mortality and incident HF.41,42
Amongst the five key proteins, PLAUR and SPP1 remained
differentially expressed after correcting for patients’ age, sex and
statin use (online supplementary Figure S3) or diabetic status
(online supplementary Figure S8). In a subgroup analysis wherein
all ischaemic patients had received angiotensin-converting enzyme
inhibitors (ACEi)/angiotensin receptor blockers (ARB) and statins,
none of the five key proteins were significant (also after adjustment
for patients’ age, sex, diabetes status and atrial fibrillation status)
(online supplementary Figures S9–S11). This suggests that their
expression was not due to drug use but rather related to underlying
ischaemic disease.
Unlike PLAUR, SPP1was the most stable differentially expressed
protein after adjustment for significant baseline clinical con-
founders (age, sex, ACEi/ARB use, beta-blocker use, statin use,
diabetes status, NT-proBNP, smoking status) (online supplemen-
tary Figures S12 and S13). SPP1 remains an interesting target for
further investigations.
Our finding on the loss of differential expression of PLAUR
after correction for the use of ACEi/ARB and/or beta-blockers is
supported by previous findings. Treatment with beta-blockers has
been associated with lower levels of PLAUR even after correction
for age, gender, hypertension, coronary artery disease, and statin
usage.43 Reduced levels of PLAUR in carotid plaques of patients
on beta-blockers suggest their possible protective role in plaque
inflammation and prevention of cardiovascular disease,43 and could
assuage eventual culmination to HF.
Looking at the prognostic patterns of the pathways in the
ischaemic nexus, we observed that for two/six pathways (i.e.
prostate cancer and regulation of superoxide anion generation)
AUC(t)s were low (Figure 4). Because there is increasing evidence
that the use of beta-blockers have anti-cancer properties (also
against prostate cancer),44–46 this is possibly due to comparatively
more men and more baseline use of beta-blockers in the index than
in the validation cohort.3
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Molecular pathways in ischaemic vs. non-ischaemic heart failure 11
Fine-tuning ACEi/ARB, beta-blocker or statin use to abrogate
levels of PLAUR, SPP1 and IGFBP1 might assuage HF deaths,
especially for the more vulnerable ischaemic cases.
Study limitations
Some potential limitations of this study should be noted. Due
to the comparison between ischaemic and non-ischaemic HF,
interpretations are limited to relative comparisons. However, the
strength of this study is the presence of two distinct HF groups
with clear definitions, enabling us to identify mechanisms that
are quantitatively relevant to ischaemic heart disease. A second
limitation of this study is the pre-selection bias of the 92 protein
biomarkers. However, we have checked for this bias in our network
enrichment analyses and found it to be a physically cohesive
network, meaning that the proteins are functionally coherent. A
third limitation is the limited number of proteins investigated. It is
therefore likely that the pathways identified are incomplete, limiting
our interpretation. However, the hypergeometric test for pathway
over-representation analysis takes into account the number of
input proteins, assuaging this limitation for the identified pathways.
Further analyses using whole-scale transcriptomics and proteomics
are expensive, but may unveil more pathways. In addition, further
analyses using class prediction methods like prediction analysis of
microarrays using nearest shrunken centroids47 could add further
insights.
A major strength of this study are the consistent outcome find-
ings in an independent validation cohort, even though it had fewer
non-ischaemic patients (a potentially heterogeneous population),
limiting the phenotypic (ischaemic vs. non-ischaemic) contrast.
The propagation of the network, based on differentially
expressed proteins, and further restriction to the circulating
proteins has enabled identification of member proteins in putative
functional modules of ischaemic heart disease and should be
further investigated.
Our results will likely inform future studies aimed at designing
clearer and more objective diagnostics and/or therapeutics for
ischaemic HF.
Conclusions
We identified pathophysiological pathways distinguishing ischaemic
from non-ischaemic heart disease. These pathways were related
to inflammation, endothelial dysfunction, superoxide production,
coagulation, and atherosclerosis. We propose five key pathway
proteins as potential treatment targets specifically for ischaemic
HF patients.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Annotation of the 92 Olink biomarkers studied herein.
Table S2. Baseline characteristics – validation cohort stratified
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